•
Sep 30, 2020
Johnson & Johnson Q3 2020 Earnings Report
Johnson & Johnson's third-quarter results reflected solid performance and positive trends across the company, driven by procedure recovery in Medical Devices, growth in Consumer Health, and strength in Pharmaceuticals.
Key Takeaways
Johnson & Johnson reported Q3 2020 results with sales of $21.1 billion, reflecting a 1.7% increase. EPS increased by 101.5% to $1.33, and adjusted EPS increased by 3.8% to $2.20. The company is increasing its full-year guidance for reported sales by $1.0 billion and adjusted EPS by $0.15.
Sales of $21.1 billion reflecting an overall and operational increase of 1.7%.
EPS of $1.33 increased 101.5%.
Adjusted EPS of $2.20 increased 3.8%.
Company is increasing guidance for Full Year Reported Sales by $1.0 billion and Adjusted EPS by $0.15.
Johnson & Johnson
Johnson & Johnson
Forward Guidance
Johnson & Johnson is increasing its full-year guidance for reported sales and adjusted EPS.
Positive Outlook
- Increasing guidance for Full Year Reported Sales by $1.0 billion.
- Increasing Adjusted EPS by $0.15.
- Strength of the recovery.
- Strong underlying business fundamentals.
- Better-than-expected procedure recovery in Medical Devices.
Challenges Ahead
- Unable to predict with reasonable certainty the ultimate outcome of legal proceedings.
- Unable to predict unusual gains and losses.
- Unable to predict acquisition-related expenses.
- Unable to predict purchase accounting fair value adjustments.
- These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.